DEX — Dextech Medical AB Share Price
Last trade - 00:00- SEK92.06m
- SEK69.91m
- 39
- 14
- 42
- 20
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.85 | ||
| Price to Tang. Book | 4.16 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -16.59% | ||
| Return on Equity | -13.21% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Dextech Medical AB is a Sweden-based research company specialized in urologic oncology. It is focused on prostate cancer, but also other cancers and non-malignant diseases. It develops drug canditates based on modified carbohydrate molecule combined with active substances. The Company has a patented technology platform, GuaDex, and three drug candidates with patents or patent applications. The portfolio includes: OsteoDex, for treatment of bone metastases in castration resistant prostate cancer (CRPC); SomaDex, based on endogenous hormone, somatostatin, and aimed at treatment of acromegaly, neuroendocrine tumors and palliative treatment of CRPC; and CatDex, for instillation treatment of bladder cancer.
Directors
- Svante Wadman CHM (66)
- Anders Holmberg CEO (68)
- Goesta Lundgren CFO (64)
- Per Asplund DRC (70)
- Rolf Eriksson DRC (67)
- Sten Nilsson DRC (71)
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- August 9th, 2004
- Public Since
- June 19th, 2014
- No. of Employees
- 1
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- AktieTorget Stock Exchange
- Shares in Issue
- 18,485,857
- Address
- Dag Hammarskjolds Vag 34A, UPPSALA, 752 37
- Web
- https://dextechmedical.com/
- Phone
- +46 86131304
- Auditors
- KPMG AB
Upcoming Events for DEX
Similar to DEX
Abera Bioscience AB
AktieTorget Stock Exchange
Aptahem AB
AktieTorget Stock Exchange
Arcede Pharma AB
AktieTorget Stock Exchange
Carbiotix AB (publ)
AktieTorget Stock Exchange
Chosa Oncology AB
AktieTorget Stock Exchange
FAQ
As of Today at 19:07 UTC, shares in Dextech Medical AB are trading at SEK4.98. This share price information is delayed by 15 minutes.
Shares in Dextech Medical AB last closed at SEK4.98 and the price had moved by +24.5% over the past 365 days. In terms of relative price strength the Dextech Medical AB share price has outperformed the FTSE Global All Cap Index by +14.39% over the past year.
There is no consensus recommendation for this security.
Dextech Medical AB does not currently pay a dividend.
Dextech Medical AB does not currently pay a dividend.
Dextech Medical AB does not currently pay a dividend.
To buy shares in Dextech Medical AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of SEK4.98, shares in Dextech Medical AB had a market capitalisation of SEK92.06m.
Here are the trading details for Dextech Medical AB:
- Country of listing: Sweden
- Exchange: AKT
- Ticker Symbol: DEX
Based on an overall assessment of its quality, value and momentum Dextech Medical AB is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Dextech Medical AB. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +6.55%.
As of the last closing price of SEK4.98, shares in Dextech Medical AB were trading -1.18% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Dextech Medical AB PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK4.98.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Dextech Medical AB's management team is headed by:
- Svante Wadman - CHM
- Anders Holmberg - CEO
- Goesta Lundgren - CFO
- Per Asplund - DRC
- Rolf Eriksson - DRC
- Sten Nilsson - DRC